Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.

All tumors were assigned an intrinsic molecular subtypes of breast cancer (luminal A, luminal B, HER2-enriched, and basal-like) and the normal-like group using the PAM50

(2015) Human Epidermal Growth Factor Receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the Immunotherapy of HER2- positive sarcoma.. Journal of

Our results show that in cultured tubular epithelial cells, the VDRA agonist paricalcitol inhibited the EGFR pathway activated by Aldo by

Effects of basic fibroblast growth factor on early revascularization and epithelial regeneration in rabbit tracheal orthotopic transplantation. Comparative anatomy, physíology,

This study analyzes whether the release of nitric oxide (NO) and thromboxane A 2 (TXA 2 ) depends on the time lapsed since gonadal function is lost, and their correlation with

Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: results of a phase I

Triple-negative breast cancer (TNBC) is am immunohistochemically-defined breast cancer subtype negative for ER, PR and HER2 expression, with dismal prognosis that

Apoptosis of osteocytes and osteoblasts precedes bone resorption and bone loss with reduced mechanical stimulation, and receptor activator of NF- ␬ B ligand (RANKL) expression